Idalopirdine fails further trials (STARBEAM and STARBRIGHT) as a treatment for Alzheimers disease -Lundbeck + Otuska

Idalopirdine (LuAE 58054),a 5HT6 antagonist being developed by Lundbeck and Otsuka for the symptomatic treatment of patients with mild to moderate Alzheimer's disease, has failed to meet primary endpoints or show benefits over placebo in its second and third Phase III trials.

The two remaining studies (STARBEAM and STARBRIGHT) in the phase III programme showed that in line with the results seen in the first study (STARSHINE) idalopirdine was safe and well tolerated. However the efficacy profile with idalopirdine observed in these studies and in the STARSHINE study did not demonstrate efficacy to support a regulatory submission. The phase III study results will be made available in the form of presentations at scientific meetings later in 2017 as well as through peer-reviewed publication.